Berk Oktem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Berk Oktem has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Appavu K. Sundaram
Agile Vaccines and Therapeutics Department, Defense Infectious Diseases Directorate, Naval Medical Research Command, Silver Spring, MD, USA
2 shared publications - Eric M. Sussman
Division of Biology, Chemistry and Materials Science (DBCMS), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, USA
2 shared publications - Jiwen Zheng
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD 20993, United States
2 shared publications - Amina S. Woods
Structural Biology Core, NIDA IRP, NIH, 333 Cassell Drive, Room 1120, Baltimore, Maryland 21224, United States
1 shared publication Bonhye Koo
Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA; Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD 20993, USA
1 shared publication- Byeong Hwa Yun
Division of Biology, Chemistry and Materials Science (DBCMS), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, USA
1 shared publication
Latest Publications
- 6 July 2023
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 2 (1) , 474-484
Thermal Extraction: An Alternative Headspace GC–MS Method for Volatile Extractables from Medical Device Materials
- 6 July 2023
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 2 (1) , 474-484
Thermal Extraction: An Alternative Headspace GC–MS Method for Volatile Extractables from Medical Device Materials
- 16 February 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (3) , 939-963
Chemical Characterization and Non-targeted Analysis of Medical Device Extracts: A Review of Current Approaches, Gaps, and Emerging Practices
The developers of medical devices evaluate the biocompatibility of their device prior to FDA’s review and subsequent introduction to the market. Chemical characterization, described in ISO 10993-18:2020, can generate information for toxicological risk assessment and is an alternative approach for addressing some biocompatibility end points (e.g., systemic toxicity, genotoxicity, carcinogenicity, reproductive/developmental toxicity) that can reduce the time and cost of testing and the need for animal testing. Additionally, chemical characterization can be used to determine whether modifications to the materials and manufacturing processes alter the chemistry of a patient-contacting device to an extent that could impact device safety. Extractables testing is one approach to chemical characterization that employs combinations of non-targeted analysis, non-targeted screening, and/or targeted analysis to establish the identities and quantities of the various chemical constituents that can be released from a device. Due to the difficulty in obtaining a priori information on all the constituents in finished devices, information generation strategies in the form of analytical chemistry testing are often used. Identified and quantified extractables are then assessed using toxicological risk assessment approaches to determine if reported quantities are sufficiently low to overcome the need for further chemical analysis, biological evaluation of select end points, or risk control. For extractables studies to be useful as a screening tool, comprehensive and reliable non-targeted methods are needed. Although non-targeted methods have been adopted by many laboratories, they are laboratory-specific and require expensive analytical instruments and advanced technical expertise to perform. In this Perspective, we describe the elements of extractables studies and provide an overview of the current practices, identified gaps, and emerging practices that may be adopted on a wider scale in the future. This Perspective is outlined according to the steps of an extractables study: information gathering, extraction, extract sample processing, system selection, qualification, quantification, and identification.
- 16 February 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (3) , 939-963
Chemical Characterization and Non-targeted Analysis of Medical Device Extracts: A Review of Current Approaches, Gaps, and Emerging Practices
The developers of medical devices evaluate the biocompatibility of their device prior to FDA’s review and subsequent introduction to the market. Chemical characterization, described in ISO 10993-18:2020, can generate information for toxicological risk assessment and is an alternative approach for addressing some biocompatibility end points (e.g., systemic toxicity, genotoxicity, carcinogenicity, reproductive/developmental toxicity) that can reduce the time and cost of testing and the need for animal testing. Additionally, chemical characterization can be used to determine whether modifications to the materials and manufacturing processes alter the chemistry of a patient-contacting device to an extent that could impact device safety. Extractables testing is one approach to chemical characterization that employs combinations of non-targeted analysis, non-targeted screening, and/or targeted analysis to establish the identities and quantities of the various chemical constituents that can be released from a device. Due to the difficulty in obtaining a priori information on all the constituents in finished devices, information generation strategies in the form of analytical chemistry testing are often used. Identified and quantified extractables are then assessed using toxicological risk assessment approaches to determine if reported quantities are sufficiently low to overcome the need for further chemical analysis, biological evaluation of select end points, or risk control. For extractables studies to be useful as a screening tool, comprehensive and reliable non-targeted methods are needed. Although non-targeted methods have been adopted by many laboratories, they are laboratory-specific and require expensive analytical instruments and advanced technical expertise to perform. In this Perspective, we describe the elements of extractables studies and provide an overview of the current practices, identified gaps, and emerging practices that may be adopted on a wider scale in the future. This Perspective is outlined according to the steps of an extractables study: information gathering, extraction, extract sample processing, system selection, qualification, quantification, and identification.
- 1 January 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 294, 279-287
Probing the mechanism of bupivacaine drug release from multivesicular liposomes
- 1 January 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 294, 279-287
Probing the mechanism of bupivacaine drug release from multivesicular liposomes